Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease  Shomron Ben–Horin, Matti Waterman, Uri Kopylov, Miri Yavzori, Orit Picard, Ella Fudim, Halim Awadie, Batia Weiss, Yehuda Chowers  Clinical Gastroenterology and Hepatology  Volume 11, Issue 4, Pages 444-447 (April 2013) DOI: 10.1016/j.cgh.2012.10.020 Copyright © 2013 AGA Institute Terms and Conditions

Figure 1 (A) Concentrations (y axis) obtained by serial measurements of infliximab level (solid markers) and ATI levels (hollow markers) in 2 exemplary patients before and after the addition of an immunomodulator at the designated time point (arrows). Each marker denotes a different measurement as plotted over time (x axis, weeks). The level of detection was 1 μg/mL for infliximab and 1.4 μg/mL for ATI. AZA, azathioprine; MTX, methotrexate. (B) Anti-TNF activity of sera was assessed by measuring TNF content in optical density (OD) after preincubation of the designated exogenous graded concentrations of recombinant TNF with serum of the patients obtained either during loss of response (triangle line) or at 3 months after the addition of azathioprine (square line). Results of experiments from 2 exemplary patients are shown. Clinical Gastroenterology and Hepatology 2013 11, 444-447DOI: (10.1016/j.cgh.2012.10.020) Copyright © 2013 AGA Institute Terms and Conditions